Scheme 1

Schematic illustration for the design and application of LA-CMGL in HCC therapy. (a) Formulation of LA-CMGL by rapid pipette mixing of acidic aqueous solution and ethanol solution. (b) Schematic illustration of LA-CMGL co-delivery of CPT/miR-145 and Gd-DOTA to achieve MRI-visible targeted therapy of HCC (i) ASGPR-mediated targeting. (ii) Lysosome escape. (iii) Synergetic antitumor mechanism of CPT and miR-145, with the released CPT inducing the apoptosis of HepG2 cells by binding to chromosomal DNA and miR-145 promoting HepG2 cells apoptosis via the SENP1-mediated HK2 SUMOylation and glycolysis pathways. iiii) MR targeted imaging and real-time monitoring of drug delivery